



February 11, 2026

To,
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

COMPANY CODE : BAYERCROP
SCRIP CODE : 506285

Dear Sir / Madam,

**Sub.: News Release - Unaudited Financial Results for the quarter ended
on December 31, 2025.**

We send herewith a copy of the News Release that is being issued by the Company today, in connection with the captioned subject.

You are requested to kindly take note of the same.

Thanking You.

Yours faithfully,

for **Bayer CropScience Limited**

Bharati Shetty
Company Secretary and Compliance Officer
(Membership No. ACS 24199)

Encl.: As above

Bayer CropScience Ltd.
CIN: L24210MH1958PLC011173

Registered and Corporate Office:
Bayer House
Central Avenue
Hiranandani Estate
Thane (West) – 400 607
Maharashtra, India

Tel : +91 22 2531 1234
Fax : +91 22 2545 5063
www.bayer.in
www.cropscience.bayer.com

RESTRICTED



Bayer Group in India
Communications
Bayer House, Central Avenue
Hiranandani Estate
Thane (West) - 400607
Maharashtra, India
www.bayer.in

News Release

Quarterly Results

Bayer CropScience Limited reports Q3 results for FY 2025-26

- Revenue from Operations of ₹ 11,062 million
- Profit Before Tax of ₹ 1,130 million

Mumbai, February 11, 2026: Bayer CropScience Limited (BSE: 506285) announced on Wednesday its unaudited results for the quarter and nine months ended December 31, 2025.

In the third quarter (Q3) of Financial Year (FY) 2025-26, Bayer CropScience Limited (BCSL) earned Revenue from Operations of ₹ 11,062 million, as compared to ₹ 10,574 million in the corresponding period of FY 2024-25. Profit Before Tax stood at ₹ 1,130 million, compared to ₹ 336 million in the corresponding period of FY 2024-25.

For the nine months ended December 31, 2025, BCSL reported Revenue from Operations of ₹ 45,742 million, compared to ₹ 44,270 million for the corresponding period in FY 2024-25. Profit Before Tax for the nine months ended December 31, 2025, stood at ₹ 6,485 million, compared to ₹ 5,395 million for the corresponding period in FY 2024-25.

Commenting on the quarterly results, Simon Wiebusch, Vice Chairman & Managing Director and CEO, BCSL, said, “In Q3, Revenue from Operations grew 5 percent, led by the continued strength of our corn seeds business. Weather volatility, particularly excess rains extending into the quarter led to limited spray windows and constrained crop protection liquidation, while a muted chili and grape season weighed on demand. We remain focused on strengthening portfolio resilience, scaling up new launches, and maintaining cost discipline to deliver consistent value.”

Vinit Jindal, Executive Director and Chief Financial Officer, Bayer CropScience Limited, added, “Q3 Profit After Tax grew by 180 percent quarter-on-quarter (24 percent year-over-year), driven by a favorable sales mix, stabilized input costs and strong financial discipline. Our ongoing working-capital improvements are strengthening financial resilience and enabling the strategic investments necessary for the company’s long-term growth.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Media Contact

Snigdha Vishal

Communications, Bayer CropScience Limited

E-mail: snigdha.vishal@bayer.com

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.